Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 11:45AM CDT
CERS: 4.79 (+0.20), HBP: 3.84 (-0.10), CIDM: 0.95 (-0.02), HNI: 51.98 (+0.71), MDSO: 57.59 (+0.05), HZO: 22.88 (-1.52), NKA: 2.06 (+0.06), NVGN: 6.54 (-0.01), EGT: 2.18 (-0.02), VLTC: 11.54 (+0.50), ADPT: 63.78 (+2.13), CALI: 2.28 (-0.05), XXII: 1.35 (-0.05), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), SIFY: 1.46 (-0.14), SCYX: 9.47 (-0.52), CLFD: 14.25 (+0.04), VGGL: 2.55 (-0.10), MOBL: 6.97 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 8:13AM CDT
PBR.A: 8.91 (+0.23), SKX: 89.66 (+2.79), SNE: 31.34 (+0.62), NVGN: 6.54 (-0.01), VLTC: 11.54 (+0.50), PBR: 9.99 (+0.59), DNKN: 54.03 (+2.52), NJ: 18.57 (+0.12), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), ERIC: 11.41 (-0.17), TXN: 54.73 (+0.01), PHM: 20.12 (+0.15), PTCT: 70.48 (-0.88), DPZ: 113.96 (+4.73), MOBL: 6.97 (-0.14)
Active Equities to Watch in the Health Care Sector -- Cytori Therapeutics, Endo Intl., BioMarin Pharma, Novogen, and Receptos
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENDP: 93.27 (-0.81), BMRN: 120.28 (-2.67), CYTX: 0.99 (+0.01), RCPT: 169.88 (-1.26), NVGN: 6.54 (-0.01)
The Health of Healthcare Companies: Complementary Research on Landmark Bancorp, Genetic Technologies, Novogen, CorMedix, and BioCryst
PR Newswire - Thu Apr 23, 6:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 8.61 (-0.22), GENE: 4.70 (-0.13), LARK: 25.20 (-0.45), BCRX: 10.35 (-0.18), NVGN: 6.54 (-0.01)
Cantrixil Receives Orphan Drug Designation from FDA
PR Newswire - Tue Apr 21, 9:27PM CDT
US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.
NVGN: 6.54 (-0.01)
Novogen (NVGN) Stock Falls Today on Private Placement
at The Street - Tue Apr 21, 10:52AM CDT
Shares of Novogen (NVGN) were down in late morning trading Monday after the Australian and U.S. biotechnology company announced it had conducted a private placement and offered rights to shareholders.
NVGN: 6.54 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 57.23 (+0.28), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), LRE: 8.69 (+0.11), LRCX: 76.70 (-0.38), MYL: 76.06 (+2.37), NVGN: 6.54 (-0.01), BIOC: 2.88 (-0.22), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04), BCLI: 4.14 (+0.02), SANM: 20.81 (-0.03)
Profit taking on deck for Novogen today; capital raise announced
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 7:02AM CDT
NVGN: 6.54 (-0.01)
Novogen Conducts Private Placement and Announces Rights Offering to Shareholders
PR Newswire - Tue Apr 21, 6:00AM CDT
Novogen Limited (ASX:NRT; NASDAQ:NVGN) ("Company" or "Novogen"
NVGN: 6.54 (-0.01)
Novogen up on cancer drug candidate pre-clinical data
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 12:38PM CDT
NVGN: 6.54 (-0.01)
Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer
PR Newswire - Mon Apr 20, 8:00AM CDT
US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN), its subsidiary, CanTx, Inc, and Yale University today disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of this drug candidate to significantly improve the survival outlook for patients with ovarian cancer. The data was presented by Professor Gil Mor of Yale Medical School to the American Association for Cancer Research (AACR) Annual Meeting.
NVGN: 6.54 (-0.01)
Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration
at The Street - Fri Apr 17, 2:12PM CDT
Shares of Novogen (NVGN) were up Friday after the company announced an MOU with the Feinstein Institute for Medical Research of New York to collaborate on brain cancer treatments.
NVGN: 6.54 (-0.01)
Novogen up 14% premarket on collaboration with Feinstein Institute in brain cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 7:46AM CDT
NVGN: 6.54 (-0.01)
Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer
PR Newswire - Fri Apr 17, 6:00AM CDT
US-Australian drug discovery company, Novogen, today announced that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research ('Feinstein Institute'
NVGN: 6.54 (-0.01)